Abstract
The histopathological diagnosis of Alzheimers disease relies on two kinds of proteinaceous aggregates: the extracellular plaques built from filaments of the Aβ-peptide and the intracellular tangles consisting of tau polymerized into Paired Helical Filaments (PHFs). The order of aggregation events is still under debate, but it is well accepted that taurelated changes have an important impact on the viability of neurons. In neurons, early morphological changes are seen in axons which begin to loose and retract synapses. This process is accompanied by an increase of aggregated tau protein. Thus the prevention of tau aggregation seems to be a valuable target for therapy of Alzheimers disease. Here we present a screening procedure by which we identified inhibitors of tau polymerization. In the primary screen we used a thioflavin-S based assay which detects PHF formation in solution. These initial hits were further analyzed for their capacity to depolymerize preformed PHFs. These results were confirmed by several secondary assays (tryptophan fluorescence, pelleting, filter trapping and electron microscopy). By this approach it is possible to identify small molecule compounds which prevent or reverse the aggregation of tau and thereby might improve the viability of neurons in a therapeutic approach.
Keywords: alzheimer, ’, s disease, neurodegenerative diseases, paired helical filaments (phfs), phosphorylation, posttranslational changes, huntington, spectroscopy, filter trapping assay
Current Alzheimer Research
Title: Screening for Inhibitors of Tau Polymerization
Volume: 2 Issue: 2
Author(s): Marcus Pickhardt, Martin von Bergen, Zuzana Gazova, Antje Hascher, Jacek Biernat, Eva-Maria Mandelkow and Eckhard Mandelkow
Affiliation:
Keywords: alzheimer, ’, s disease, neurodegenerative diseases, paired helical filaments (phfs), phosphorylation, posttranslational changes, huntington, spectroscopy, filter trapping assay
Abstract: The histopathological diagnosis of Alzheimers disease relies on two kinds of proteinaceous aggregates: the extracellular plaques built from filaments of the Aβ-peptide and the intracellular tangles consisting of tau polymerized into Paired Helical Filaments (PHFs). The order of aggregation events is still under debate, but it is well accepted that taurelated changes have an important impact on the viability of neurons. In neurons, early morphological changes are seen in axons which begin to loose and retract synapses. This process is accompanied by an increase of aggregated tau protein. Thus the prevention of tau aggregation seems to be a valuable target for therapy of Alzheimers disease. Here we present a screening procedure by which we identified inhibitors of tau polymerization. In the primary screen we used a thioflavin-S based assay which detects PHF formation in solution. These initial hits were further analyzed for their capacity to depolymerize preformed PHFs. These results were confirmed by several secondary assays (tryptophan fluorescence, pelleting, filter trapping and electron microscopy). By this approach it is possible to identify small molecule compounds which prevent or reverse the aggregation of tau and thereby might improve the viability of neurons in a therapeutic approach.
Export Options
About this article
Cite this article as:
Pickhardt Marcus, Bergen von Martin, Gazova Zuzana, Hascher Antje, Biernat Jacek, Mandelkow Eva-Maria and Mandelkow Eckhard, Screening for Inhibitors of Tau Polymerization, Current Alzheimer Research 2005; 2 (2) . https://dx.doi.org/10.2174/1567205053585891
DOI https://dx.doi.org/10.2174/1567205053585891 |
Print ISSN 1567-2050 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5828 |
Call for Papers in Thematic Issues
New Advances in the Prevention, Diagnosis, Treatment, and Rehabilitation of Alzheimer's Disease
Aims and Scope: Introduction: Alzheimer's disease (AD) poses a significant global health challenge, with an increasing prevalence that demands concerted efforts to advance our understanding and strategies for prevention, diagnosis, treatment, and rehabilitation. This thematic issue aims to bring together cutting-edge research and innovative approaches from multidisciplinary perspectives to address ...read more
Current updates on the Role of Neuroinflammation in Neurodegenerative Disorders
Neuroinflammation is an invariable hallmark of chronic and acute neurodegenerative disorders and has long been considered a potential drug target for Alzheimer?s disease (AD) and dementia. Significant evidence of inflammatory processes as a feature of AD is provided by the presence of inflammatory markers in plasma, CSF and postmortem brain ...read more
Deep Learning for Advancing Alzheimer's Disease Research
Alzheimer's disease (AD) poses a significant global health challenge, with an increasing number of individuals affected yearly. Deep learning, a subfield of artificial intelligence, has shown immense potential in various domains, including healthcare. This thematic issue of Current Alzheimer Research explores the application of deep learning techniques in advancing our ...read more
Diagnostic and therapeutic biomarkers of dementia
Dementia affects 18 million people worldwide. Dementia is a syndrome of symptoms caused by brain disease, usually chronic or progressive, clinically characterized by multiple impairments of higher cortical functions such as memory, thinking, orientation, and learning. In addition, in the course of dementia, cognitive deficits are observed, which often hinder ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Designing of Novel Carbonic Anhydrase Inhibitors and Activators
Current Medicinal Chemistry - Cardiovascular & Hematological Agents The Effects of Italian Mediterranean Organic Diet (IMOD) on Health Status
Current Pharmaceutical Design Nanotechnology as an Adjunct Tool for Transplanting Engineered Cells and Tissues
Current Molecular Medicine Histone Acetylation as a Potential Therapeutic Target in Motor Neuron Degenerative Diseases
Current Pharmaceutical Design Oral Health in Alzheimers Disease: A Review
Current Alzheimer Research Editorial (BIOQUEST India: A Global Biotechnology Forum for Knowledge-Based Innovation and Sustainable Development)
Current Pharmacogenomics and Personalized Medicine Treatment Strategies Against Diabetic Foot Ulcer: Success so Far and the Road Ahead
Current Diabetes Reviews β-Lactams as Neuroprotective Agents
Anti-Infective Agents in Medicinal Chemistry Mechanisms of Control of Neuron Survival by the Endocannabinoid System
Current Pharmaceutical Design Tetramethoxyluteolin for the Treatment of Neurodegenerative Diseases
Current Topics in Medicinal Chemistry A Systematic Review on the Sinomenine Derivatives
Mini-Reviews in Medicinal Chemistry Protein Homeostasis as a Therapeutic Target for Diseases of Protein Conformation
Current Topics in Medicinal Chemistry Role of Glycosphingolipids and Therapeutic Perspectives on Alzheimers Disease
CNS & Neurological Disorders - Drug Targets Frontotemporal Dementia Caused by CHMP2B Mutations
Current Alzheimer Research Metal Ion Complexes with Pyrazoles, Aziridines and Diaziridines – Synthesis and Biological Activity
Current Medicinal Chemistry Pharmacological Prolyl Hydroxylase Domain Inhibition as a Therapeutic Target for Parkinson’s Disease
CNS & Neurological Disorders - Drug Targets Structurally Unprecedented Metabolites from Marine Sponges
Current Organic Chemistry Drug Repurposing for the Treatment of Staphylococcal Infections
Current Pharmaceutical Design Meet Our Associate Editor
Current Molecular Medicine Single Nucleotide Polymorphisms (SNPs): History, Biotechnological Outlook and Practical Applications
Current Pharmacogenomics